Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy

CNS Spectrums

Volumn 19, Issue 6, 2013, Pages 528-534

  Nelson, J Craig ^a   Rahman, Zia ^b   Laubmeier, Kimberly K ^c   Eudicone, James M ^b   McQuade, Robert D ^c   Berman, Robert M ^b   Marcus, Ronald N ^b   Baker, Ross A ^c   Sheehan, John J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Adjunctive treatment; Antidepressant; Inadequate response; Major depressive disorder; Symptom worsening

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AKATHISIA; ARTICLE; BLURRED VISION; BRUXISM; CONSTIPATION; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HAMILTON SCALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESTLESSNESS; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA; ADULT; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84912137642     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291300103X     Document Type: Article

References (30)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996; 19(2): 179-200.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006; 163(11): 1905-1917.
3. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007; 68(Suppl 8): 17-25.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2010; 167(10): A34.
5. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9): 980-991.
6. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010; 71(Suppl E1): e08.
7. Baghai TC, Blier P, Baldwin DS, et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2011; 261(Suppl 3): 207-245.
8. Nelson JC. Augmentation strategies in the treatment of major depressive disorder: recent findings and current status of augmentation strategies. CNS Spectr. 2007; 12(Suppl 22): 6-9.
9. Nelson J, Thase M, Bellocchio E, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012; 27(3): 125-133.
10. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008; 28(2): 156-165.
11. Berman R, Fava M, Thase M, et al. Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009; 14(4): 197-206.
12. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68(6): 843-853.
13. Chernoloz O, El Mansari M, Blier P. Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl). 2009; 206(2): 335-344.
14. Lakoski JM, Aghajanian GK. Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology. 1985; 24(4): 265-273.
15. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007; 68(2): 224-236.
16. McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs. 2010; 19(12): 1527-1544.
17. Blier P, Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord. 2011; 128(Suppl 1): S3-S10.
18. Fava GA. Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychother Psychosom. 1994; 61(3-4): 125-131.
19. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003; 64(2): 123-133.
20. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008; 23(2): 70-83.
21. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117(Suppl 1): S26-S43.
22. Muzina DJ, Chambers J, Camacho T, et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care. 2011; 17(12): 793-801.
23. Casey D, Laubmeier K, Marler S, Forbes R, Baker R. Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response. Prim Care Comp for CNS Disorders. 2012; 14(3):pii: PCC.11m01251. doi: 10.4088/PCC.4011m01251.
24. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009; 70(Suppl 6): 16-25.
25. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166(9): 980-991.
26. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009; 14(4): 197-206.
27. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68(6): 843-853.
28. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008; 28(2): 156-165.
29. Nelson JC, Thase ME, Bellocchio EE, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012; 27(3): 125-133.
30. Abilify® (aripiprazole). Full prescribing information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2013.